[go: up one dir, main page]

BR122018014454B8 - forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol - Google Patents

forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol

Info

Publication number
BR122018014454B8
BR122018014454B8 BR122018014454A BR122018014454A BR122018014454B8 BR 122018014454 B8 BR122018014454 B8 BR 122018014454B8 BR 122018014454 A BR122018014454 A BR 122018014454A BR 122018014454 A BR122018014454 A BR 122018014454A BR 122018014454 B8 BR122018014454 B8 BR 122018014454B8
Authority
BR
Brazil
Prior art keywords
methylpropyl
dimethylamino
ethyl
phenol hydrochloride
crystalline form
Prior art date
Application number
BR122018014454A
Other languages
English (en)
Other versions
BR122018014454B1 (pt
Inventor
Fischer Andreas
Lischke Dagmar
Buschmann Helmut
Gruss Michael
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122018014454(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR122018014454B1 publication Critical patent/BR122018014454B1/pt
Publication of BR122018014454B8 publication Critical patent/BR122018014454B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

formas cristalinas sólidas de cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol. a invenção se refere a uma nova forma cristalina de cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol, métodos para sua preparação e uso, e composições farmacêuticas que a contém.
BR122018014454A 2004-06-28 2005-06-27 forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol BR122018014454B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
BRPI0512792-0A BRPI0512792A (pt) 2004-06-28 2005-06-27 formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol
PCT/EP2005/006884 WO2006000441A2 (en) 2004-06-28 2005-06-27 Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (2)

Publication Number Publication Date
BR122018014454B1 BR122018014454B1 (pt) 2019-09-03
BR122018014454B8 true BR122018014454B8 (pt) 2021-07-27

Family

ID=34925507

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018014454A BR122018014454B8 (pt) 2004-06-28 2005-06-27 forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
BRPI0512792-0A BRPI0512792A (pt) 2004-06-28 2005-06-27 formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0512792-0A BRPI0512792A (pt) 2004-06-28 2005-06-27 formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol

Country Status (27)

Country Link
US (16) US20070213405A1 (pt)
EP (2) EP1612203B1 (pt)
JP (1) JP4990764B2 (pt)
KR (1) KR101096501B1 (pt)
CN (1) CN1997621B (pt)
AR (2) AR049949A1 (pt)
AT (2) ATE368639T1 (pt)
AU (1) AU2005256512B2 (pt)
BR (2) BR122018014454B8 (pt)
CA (1) CA2572147C (pt)
CY (2) CY1106929T1 (pt)
DE (2) DE602004007905T2 (pt)
DK (2) DK1612203T3 (pt)
EC (1) ECSP17046065A (pt)
ES (2) ES2291780T3 (pt)
HR (1) HRP20110050T8 (pt)
IL (1) IL180373A (pt)
MX (1) MXPA06014741A (pt)
NO (3) NO338605B1 (pt)
NZ (1) NZ551605A (pt)
PE (1) PE20060372A1 (pt)
PL (2) PL1612203T3 (pt)
PT (2) PT1612203E (pt)
RU (1) RU2423345C2 (pt)
SI (2) SI1612203T1 (pt)
WO (1) WO2006000441A2 (pt)
ZA (1) ZA200700774B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
PT1612203E (pt) * 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
DK3173400T3 (da) 2007-12-07 2019-11-25 Gruenenthal Gmbh Medikamenter, der indeholder krystallinske modifikationer af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
NZ588863A (en) 2008-05-09 2012-08-31 Gruenenthal Chemie Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
PL2456427T3 (pl) 2009-07-22 2015-07-31 Gruenenthal Gmbh Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
US8288592B2 (en) * 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
WO2011138037A2 (de) 2010-05-05 2011-11-10 Ratiopharm Gmbh Festes tapentadol in nicht-kristalliner form
EP3656765B1 (en) * 2010-07-23 2021-04-14 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
HUE027514T2 (en) * 2011-03-04 2016-10-28 Gruenenthal Gmbh Parenteral administration of tapentadol
PT2680832T (pt) 2011-03-04 2019-10-28 Gruenenthal Gmbh Formulação farmacêutica aquosa de tapentadol para administração oral
EP3290029B1 (en) 2011-03-04 2020-09-02 Grünenthal GmbH Semisolid aqueous pharmaceutical composition containing tapentadol
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
PT2736495T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente à adulteração proporcionando libertação imediata de fármaco
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AR090695A1 (es) 2012-04-18 2014-12-03 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
USD730877S1 (en) 2013-09-06 2015-06-02 Plantronics, Inc. Communications headset
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
KR20170132282A (ko) 2015-03-27 2017-12-01 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여를 위한 안정한 제형
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
PT3445742T (pt) 2016-04-19 2020-02-19 Ratiopharm Gmbh Fosfato de tapentadol cristalino
EA201990744A1 (ru) 2016-09-23 2019-08-30 Грюненталь Гмбх Стабильная лекарственная форма для парентерального введения тапентадола
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
CA3196954A1 (en) 2020-11-03 2022-05-12 Josep Bassaganya-Riera Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
JP3631763B2 (ja) * 1996-08-14 2005-03-23 ジー・ディー・サール・アンド・カンパニー ４―［５―メチル―３―フェニルイソキサゾル―４―イル］ベンゼンスルホンアミドの結晶形
CN100338028C (zh) * 2000-10-31 2007-09-19 山道士有限公司 盐酸文拉法辛的晶形
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
WO2003024916A1 (fr) * 2001-09-13 2003-03-27 Kissei Pharmaceutical Co., Ltd. Cristaux d'un derive d'hydroxynorephedrine
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
PT1612203E (pt) * 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
DK3173400T3 (da) * 2007-12-07 2019-11-25 Gruenenthal Gmbh Medikamenter, der indeholder krystallinske modifikationer af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

Also Published As

Publication number Publication date
US20120302643A1 (en) 2012-11-29
NO20160914A1 (no) 2007-01-24
CN1997621A (zh) 2007-07-11
DK1612203T3 (da) 2007-12-03
DK1799633T3 (da) 2011-03-28
HRP20110050T1 (hr) 2011-02-28
US20190062263A1 (en) 2019-02-28
NO20070162L (no) 2007-01-24
US20200102261A1 (en) 2020-04-02
US20140296346A1 (en) 2014-10-02
ATE368639T1 (de) 2007-08-15
PT1799633E (pt) 2011-03-07
CN1997621B (zh) 2011-06-15
ES2359504T3 (es) 2011-05-24
NO338605B1 (no) 2016-09-12
PL1612203T3 (pl) 2007-12-31
US20160122287A1 (en) 2016-05-05
MXPA06014741A (es) 2007-02-12
US20180029976A1 (en) 2018-02-01
PL1799633T3 (pl) 2011-06-30
JP4990764B2 (ja) 2012-08-01
ES2291780T3 (es) 2008-03-01
CY1111530T1 (el) 2015-08-05
ZA200700774B (en) 2008-09-25
WO2006000441A2 (en) 2006-01-05
EP1612203A1 (en) 2006-01-04
US20230174458A1 (en) 2023-06-08
EP1612203B1 (en) 2007-08-01
NO343922B1 (no) 2019-07-08
CA2572147C (en) 2012-10-30
DE602005026031D1 (de) 2011-03-03
RU2423345C2 (ru) 2011-07-10
KR20070039929A (ko) 2007-04-13
IL180373A0 (en) 2007-06-03
US20200385334A1 (en) 2020-12-10
US20140011886A1 (en) 2014-01-09
RU2007103297A (ru) 2008-08-10
SI1612203T1 (sl) 2007-12-31
ECSP17046065A (es) 2018-11-30
SI1799633T1 (sl) 2011-05-31
BRPI0512792A (pt) 2008-04-08
NO20171103A1 (no) 2007-01-24
EP1799633B1 (en) 2011-01-19
AU2005256512B2 (en) 2011-05-19
JP2008504326A (ja) 2008-02-14
ATE496021T1 (de) 2011-02-15
US20110294898A1 (en) 2011-12-01
KR101096501B1 (ko) 2011-12-20
US20100160447A1 (en) 2010-06-24
US20180230082A1 (en) 2018-08-16
NZ551605A (en) 2010-01-29
US7994364B2 (en) 2011-08-09
US20070213405A1 (en) 2007-09-13
AU2005256512A1 (en) 2006-01-05
HRP20110050T8 (en) 2011-03-31
AR116052A2 (es) 2021-03-25
CA2572147A1 (en) 2006-01-05
PT1612203E (pt) 2007-08-20
US20210261492A1 (en) 2021-08-26
WO2006000441A3 (en) 2006-05-04
PE20060372A1 (es) 2006-05-08
IL180373A (en) 2012-05-31
US20170166515A1 (en) 2017-06-15
DE602004007905T2 (de) 2008-05-08
NO341239B1 (no) 2017-09-25
CY1106929T1 (el) 2012-09-26
DE602004007905D1 (de) 2007-09-13
AR049949A1 (es) 2006-09-20
US20090186947A1 (en) 2009-07-23
BR122018014454B1 (pt) 2019-09-03
EP1799633A2 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
BR122018014454B8 (pt) forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
NO20171811A1 (no) Fremgangsmåte for fremstilling av (1R,2R)-3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol
CR8717A (es) Nuevos compuestos
AR058753A1 (es) Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
DK2101569T3 (da) Krystallinsk fast rasagilinbase
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
ECSP10010661A (es) Dronedarona para la prevención de la cardioversión
BRPI0516464B8 (pt) método para a preparação de um produto farmacêutico
CL2011001590A1 (es) Compuesto estaminico 2-metil-1-fenil-2-(piridin-2-il)propano-1-amina o su isomero s, antagonista de nmda; y su uso para la terapia de la depresion.
UY28762A1 (es) Nuevos compuestos
BRPI0511819A (pt) sais de guanilidrazona, composições, processos de fabricação e métodos de uso
BRPI0819460A2 (pt) Uso de uma proteína, composição oralmente administrável, métodos para reduzir as propriedades de erosão dental, e para reduzir a erosão dental
EA200970167A1 (ru) Фармацевтическая композиция, содержащая комбинацию саредутанта и селективного ингибитора обратного захвата серотонина или ингибитора обратного захвата серотонина/норэпинефрина
EA200701180A1 (ru) Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств
BRPI0823286A2 (pt) Dois tipos de formas cristalinas de pinocembrina, sua preparação e seu uso para a fabricação de composições farmacêuticas.
ITPD20050346A1 (it) Uso di nuovi composti endocannabinoido simili,nonche' metodo di preparazione e composizioni farmaceutiche ottenibili con gli stessi

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO